| Literature DB >> 32087306 |
Jean-Luc Brun1, Bernard Castan2, Bertille de Barbeyrac3, Charles Cazanave3, Amélie Charvériat4, Karine Faure5, Stéphanie Mignot4, Renaud Verdon6, Xavier Fritel4, Olivier Graesslin7.
Abstract
Pelvic inflammatory diseases (PID) must be suspected when spontaneous pelvic pain is associated with induced adnexal or uterine pain (grade B). Pelvic ultrasonography is necessary to rule out tubo-ovarian abscess (TOA) (grade C). Microbiological diagnosis requires endocervical and TOA sampling for molecular and bacteriological analysis (grade B). First-line treatment for uncomplicated PID combines ceftriaxone 1 g, once, IM or IV, doxycycline 100 mg ×2/day, and metronidazole 500 mg ×2/day PO for 10 days (grade A). First-line treatment for complicated PID combines IV ceftriaxone 1-2 g/day until clinical improvement, doxycycline 100 mg ×2/day, IV or PO, and metronidazole 500 mg ×3/day, IV or PO for 14 days (grade B). Drainage of TOA is indicated if the pelvic fluid collection measures more than 3 cm (grade B). Follow-up is required in women with sexually transmitted infections (STIs) (grade C). The use of condoms is recommended (grade B). Vaginal sampling for microbiological diagnosis is recommended 3-6 months after PID (grade C), before the insertion of an intrauterine device (grade B), and before elective termination of pregnancy or hysterosalpingography. When specific bacteria are identified, antibiotics targeted at them are preferable to systematic antibiotic prophylaxis.Entities:
Keywords: Antibiotics; Bacteriological sampling; Follow-up; Pelvic inflammatory disease; Tubo-ovarian abscess
Mesh:
Substances:
Year: 2020 PMID: 32087306 DOI: 10.1016/j.jogoh.2020.101714
Source DB: PubMed Journal: J Gynecol Obstet Hum Reprod ISSN: 2468-7847